Přejít k obsahu
Merck
Všechny fotografie(1)

Hlavní dokumenty

Zobrazit celou dokumentaci

M2305000

Mitoxantrone hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonyma:

Mitoxantrone dihydrochloride, 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C22H28N4O6 · 2HCl
Číslo CAS:
70476-82-3
Molekulová hmotnost:
517.40
MDL number:
MFCD00242943
UNSPSC Code:
41116107
PubChem Substance ID:
329817936
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

mitoxantrone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl[H].Cl[H].OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12

InChI

1S/C22H28N4O6.2ClH/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;;/h1-4,23-30H,5-12H2;2*1H

InChI key

ZAHQPTJLOCWVPG-UHFFFAOYSA-N

Gene Information

human ... TOP2A(7153)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Mitoxantrone hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Mitoxantrone is a cytostatic anthracenedione that intercalates in DNA and increases the incidence of double-strand breaks by stabilizing the cleavable complex of topoisomerase II and DNA. Mitoxantrone also displays broad immunosuppressive activity inhibiting proliferation of all classes of lymphocytes and inducing apoptosis of antigen-presenting T cells. It used clinically as a chemotherapeutic agent against leukemias and solid tumors and as an immune system modulator in multiple sclerosis.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H340,H360

Hazard Classifications

Muta. 1B - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 9

1 of 9

Indocyanine green United States Pharmacopeia (USP) Reference Standard

USP

1340009

Indocyanine green

Doxorubicin hydrochloride British Pharmacopoeia (BP) Reference Standard

BP990

Doxorubicin hydrochloride

Etoposide European Pharmacopoeia (EP) Reference Standard

E2600000

Etoposide

Ko143 hydrate ≥98% (HPLC)

Sigma-Aldrich

K2144

Ko143 hydrate

Doxorubicin hydrochloride suitable for fluorescence, 98.0-102.0% (HPLC)

Sigma-Aldrich

44583

Doxorubicin hydrochloride

Daunorubicin hydrochloride ≥90% (HPLC)

Sigma-Aldrich

30450

Daunorubicin hydrochloride

Doxorubicin hydrochloride European Pharmacopoeia (EP) Reference Standard

D2975000

Doxorubicin hydrochloride

Benserazide hydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

B7283

Benserazide hydrochloride

Cisplatin European Pharmacopoeia (EP) Reference Standard

C2210000

Cisplatin

Hui Zhang et al.
Cancer letters, 350(1-2), 61-68 (2014-04-22)
AST1306, an inhibitor of EGFR and ErbB2, is currently in phase I of clinical trials. We evaluated the effect of AST306 on the reversal of multidrug resistance (MDR) induced by ATP-binding cassette (ABC) transporters. We found that AST1306 significantly sensitized
Jurjen M Ruben et al.
Cancer immunology, immunotherapy : CII, 63(4), 335-345 (2014-01-05)
Since few leukemia-associated antigens (LAA) are characterized for acute myeloid leukemia (AML), apoptotic tumor cells constitute an attractive LAA source for DC-based vaccines, as they contain both characterized and unknown LAA. However, loading DC with apoptotic tumor cells may interfere
Thiruganesh Ramasamy et al.
Journal of biomedical nanotechnology, 10(7), 1304-1312 (2014-05-09)
Combination of two or more drugs has emerged as a promising strategy to elicit synergistic therapeutic responses that can overcome multidrug resistance of cancer cells at various stages of the growth cycle. In the current study, we investigated the efficacy
Florence Joly et al.
BJU international, 115(1), 65-73 (2013-11-05)
To evaluate the overall benefits of non-taxane chemotherapies in a non-selected population including unfit patients presenting with symptoms and pain. This randomized phase II study reports data from 92 patients (52% >70 years old; 40% with a performance score of
Robert S Nickel et al.
Pediatric blood & cancer, 61(5), 810-814 (2013-12-21)
Daunorubicin, a component of the four-drug induction chemotherapy regimen for de novo pediatric high-risk acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy), was unavailable in 2011 due to a national drug shortage. During this time, our institution substituted mitoxantrone 6.25
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.